Three New Medicines — Three More Steps Towards Systematic Treatment Accessibility

In the first half of 2025, Darnytsia launched three new medicinal products on the market. These are antidepressants, modern anti-inflammatory and pain-relieving drugs with a pronounced antirheumatic effect.

We are addressing therapeutic “bottlenecks” where patients face limited choices, import dependence, or outdated molecules. The focus is on those conditions that have become more widespread during the war.

Since the beginning of the full-scale invasion, Darnytsia has brought more than 40 new medicines to the market. This is not a marketing race, but a systematic response to new healthcare demands. We are building a range of relevant, proven, and economically accessible therapies — with no compromise on quality.

Our goal is to make quality treatment accessible to everyone. That is why, since February 2025, we have reduced prices by 30% on 20 of the most in-demand medicines.

Our production facilities comply with GMP standards and regularly undergo international audits. Thanks to this, Darnytsia’s medicines are already present in more than 20 countries. However, our main goal is not export, but a sovereign pharmaceutical system in Ukraine.

“We work every day to ensure that modern, effective, and safe medicines are accessible to every Ukrainian. Launching new products on the market is our contribution to the nation’s health and support for people during the full-scale war. We believe that caring for the patient starts with quality, innovation, and responsibility,” says Inna Denyak, Development Director at Darnytsia Pharmaceutical Company.